ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Jazz Pharmaceuticals and BeOne Medicines side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Jazz PharmaceuticalsBeOne Medicines
studies on the registry223195
open to participants now1851
phase 3 studies under way719
reach primary completion within a year823
programswith a study of their own in two years824

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseJazz PharmaceuticalsBeOne Medicines
Phase 1

Jazz Pharmaceuticals: 3 of its 8 programs at phase 1

  1. JZP047phase 1
  2. JZP269phase 1
  3. JZP441phase 1
38%
67%
Phase 2

Jazz Pharmaceuticals: 2 of its 8 programs at phase 2

  1. zeltipronephase 2
  2. lurbinectedinphase 2
25%

BeOne Medicines: 1 of its 24 programs at phase 2

  1. BGB-45035phase 2
4%
Phase 3

Jazz Pharmaceuticals: 1 of its 8 programs at phase 3

  1. zanidatamabphase 3
13%

BeOne Medicines: 6 of its 24 programs at phase 3

  1. sonrotoclaxphase 3
  2. tislelizumabphase 3
  3. tacabrutidegphase 3
  4. Anti-GPC3/Anti-4-1BB Bispecific Antibody BGB-B2033phase 3
  5. CDK4 Inhibitor BGB-43395phase 3

and 1 more — sign in to see them all

25%
Approved, new studies

Jazz Pharmaceuticals: 2 of its 8 programs at approved, new studies

  1. Cannabidiolapproved, new study
  2. JZP258approved, new study
25%

BeOne Medicines: 1 of its 24 programs at approved, new studies

  1. zanubrutinibapproved, new study
4%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Jazz Pharmaceuticals5 readouts · 1 phase 3

Jazz Pharmaceuticals, Nov ’26: 1 program whose next study reaches primary completion

  1. JZP047phase 1 · Nov 30 · NCT07377539

Jazz Pharmaceuticals, Dec ’26: 1 program whose next study reaches primary completion

  1. zanidatamabphase 3 · Dec 31 · NCT06695845
·

Jazz Pharmaceuticals, Feb ’27: 1 program whose next study reaches primary completion

  1. JZP269phase 1 · Feb 27 · NCT07813663

Jazz Pharmaceuticals, Mar ’27: 1 program whose next study reaches primary completion

  1. zeltipronephase 2 · Mar 31 · NCT04541082
····

Jazz Pharmaceuticals, Aug ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. Cannabidiolapproved, new study · Aug 1 · NCT05044819
··
BeOne Medicines10 readouts · 1 phase 3

BeOne Medicines, Nov ’26: 4 programs whose next study reaches primary completion

  1. sonrotoclaxphase 3 · Nov 0 · NCT04973605
  2. tislelizumabphase 3 · Nov 0 · NCT03736889
  3. CDK4 Inhibitor BGB-43395phase 3 · Nov 22 · NCT07820891
  4. tacabrutidegphase 3 · Nov 30 · NCT07005713

BeOne Medicines, Dec ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. zanubrutinibapproved, new study · Dec 31 · NCT04170283
··

BeOne Medicines, Mar ’27: 1 program whose next study reaches primary completion

  1. Anti-GPC3/Anti-4-1BB Bispecific Antibody BGB-B2033phase 3 · Mar 31 · NCT06427941
···

BeOne Medicines, Jul ’27: 2 programs whose next study reaches primary completion

  1. PRMT5 Inhibitor BGB-58067phase 1 · Jul 1 · NCT07712640
  2. Bcl-2 Inhibitor BGB-21447phase 1 · Jul 30 · NCT06756932
·

BeOne Medicines, Sep ’27: 1 program whose next study reaches primary completion

  1. Anti-B7-H4 Antibody Drug Conjugate BG-C9074phase 3 · Sep 28 · NCT06233942

BeOne Medicines, Oct ’27: 1 program whose next study reaches primary completion

  1. BON-107phase 1 · Oct 11 · NCT07934069
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 21, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Jazz Pharmaceuticals

New programs 1

  • JZP269phase 1 · first study · Sep 4

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 3

BeOne Medicines

New programs 6

  • BON-C1393phase 1 · first study · Oct 23
  • BON-107phase 1 · first study · Oct 22
  • BG-92505phase 1 · first study · Oct 21
  • BON-106phase 1 · first study · Oct 19 · Neoplasm Metastasis
  • BG-T0920phase 1 · first study · Oct 15 · Lymphoma, Large B-Cell, Diffuse
  • BG-T0050phase 1 · first study · Oct 12 · Lymphoma, Large B-Cell, Diffuse

Reached a new phase 2

Study stopped 0

None

Primary completion later 2

Where they overlap

Conditions where at least two of them have programs: 2 in all. A program counts in each condition its studies name most.

ConditionJazz PharmaceuticalsBeOne Medicines
Breast Neoplasmsboth · compare here

Jazz Pharmaceuticals in Breast Neoplasms: 2 programs

  1. zanidatamabphase 3
  2. lurbinectedinphase 2

Their studies: Jazz Pharmaceuticals’ studies of Breast Neoplasms in search

Stomach Neoplasmsboth · compare here

Jazz Pharmaceuticals in Stomach Neoplasms: 1 program

  1. zanidatamabphase 3

Their studies: Jazz Pharmaceuticals’ studies of Stomach Neoplasms in search

BeOne Medicines in Stomach Neoplasms: 1 program

  1. tislelizumabphase 3

Their studies: BeOne Medicines’ studies of Stomach Neoplasms in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Jazz Pharmaceuticals 3 of 8 · BeOne Medicines 12 of 24 programs (15 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.